Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 856 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Effect Neonatal Clear all
Withdrawn No phase listed Observational

Effect of Laser Treatment on Capillary Malformations

NCT02035319
View directory record Official record
Conditions
Capillary Malformation, Port Wine Stain
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Phase 2 Interventional

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

NCT05725902
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

NCT01161537
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Not applicable Interventional Results available

Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass

NCT01595386
View directory record Official record
Conditions
Heart Disease Congenital Complex
Interventions
Hydrocortisone, Normal Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 28 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of a Healthy Snack on Radiance, Aging and Inflammation of the Skin

NCT04352504
View directory record Official record
Conditions
Skin Laxity
Interventions
Almond, Pretzel
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 27, 2026, 11:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

NCT02966028
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease, ESRD, Coronary Artery Calcification
Interventions
SNF472, Placebo
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
46
States / cities
Bakersfield, California • Chula Vista, California • Escondido, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Aerobic Exercise, Balance Training, and Ataxia

NCT03745248
View directory record Official record
Conditions
Ataxia, Spino Cerebellar Degeneration, Spinocerebellar Ataxias
Interventions
Aerobic training, Balance Training
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 27, 2026, 11:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular Effects of Prenatal Methamphetamine Exposure

NCT04616625
View directory record Official record
Conditions
Methamphetamine Abuse, Newborn Complication | Patient | Neonatalology
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Marysville, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Phase 3 Interventional

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

NCT00406926
View directory record Official record
Conditions
Turner Syndrome
Interventions
Somatropin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
9 Months to 4 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2006 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Massage Therapy in Premature Neonates

NCT06163586
View directory record Official record
Conditions
Neonatal Prematurity, Massage Therapy
Interventions
Neonatal Touch and Massage Therapy
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
24 Weeks to 32 Weeks
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

NCT00493961
View directory record Official record
Conditions
Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions
gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 27, 2026, 11:47 PM EDT
Recruiting No phase listed Observational

Pompe Pregnancy Sub-Registry

NCT00567073
View directory record Official record
Conditions
Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Interventions
Not listed
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2034
U.S. locations
15
States / cities
Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

NCT02664441
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 27, 2026, 11:47 PM EDT
Not listed Not applicable Interventional

Effects of Mother's Voice and Heartbeat Sounds on Preterm Newborns

NCT01913288
View directory record Official record
Conditions
Preterm Birth
Interventions
Biological Maternal Sounds
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
24 Weeks to 34 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

NCT01484873
View directory record Official record
Conditions
Obesity, Overweight, Craniopharyngioma
Interventions
Exenatide
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 27, 2026, 11:47 PM EDT
Recruiting Not applicable Interventional

Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Meconium Exposure

NCT07274527
View directory record Official record
Conditions
Neonatal Respiratory Distress Related Conditions, Meconium, Perinatal Morbidity, Neonatal Acidosis, Cord Blood, Neonatal Brain Injury, Maternal Morbidity, Mechanical Ventilation, CPAP, Surfactant, Perinatal Death, Amnioinfusion, NICU Admission
Interventions
Intrauterine pressure catheter, Standard obstetric care at discretion of delivery provider
Device · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Early Phase 1 Interventional

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

NCT05891119
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab
Dietary Supplement · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

NCT03872401
View directory record Official record
Conditions
Coronary Heart Disease (CHD)
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 79 Years
Enrollment
12,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
145
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Not applicable Interventional Results available

Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

NCT01869777
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Mast Cell Leukemia, Myeloid/NK-cell Acute Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
bioelectric impedance analysis
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 27, 2026, 11:47 PM EDT
Active, not recruiting No phase listed Observational

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

NCT05675436
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss, Hbsc, Sickle Beta Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Syndrome Variant
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
16 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 27, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms

NCT01893892
View directory record Official record
Conditions
Musculoskeletal Complications
Interventions
levocarnitine, placebo, questionnaire administration
Dietary Supplement · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 27, 2026, 11:47 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers

NCT00617292
View directory record Official record
Conditions
Adrenal Hyperplasia, Congenital
Interventions
Not listed
Lead sponsor
Office of Rare Diseases (ORD)
NIH
Eligibility
12 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2008 · Synced Oct 27, 2026, 11:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transfusion of Older Stored Red Cells

NCT01534676
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Transfusion, Blood, Chelation therapy
Procedure · Biological
Lead sponsor
Columbia University
Other
Eligibility
1 Year to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 27, 2026, 11:47 PM EDT